ABOUT THE COMPANY
Augustine Therapeutics was founded in 2019 as a spin-off of VIB and KU Leuven. Based on the groundbreaking neurological research of Prof. Ludo Van Den Bosch, Prof. Joris De Wit and Prof. Bart De Strooper, this early drug discovery company is building a portfolio of first-in-class therapies for rare neuromuscular diseases and neurodegenerative disorders. Augustine Therapeutics’ approach is based on new insights into the neuroprotective potential of small-molecule HDAC6 inhibitors.
HDAC6 was identified by Prof. Ludo Van Den Bosch and his research group a decade ago as a potential therapeutic target for Charcot-Marie-Tooth (CMT) disease. Our research aims to deepen our understanding of CMT biology and characterize the potential protective action of HDAC6 inhibitors at the neuronal and axonal level.
Augustine Therapeutics is supported by experienced scientists and drug developers from major pharma and biotech companies and is backed by V-Bio Ventures, PMV, AdBio Partners, VIB New Venture and Gemma Frisius Fund. Together, these investors contributed around € 8 million seed funding since the company inception in 2019. Our research is also well funded by Flanders Innovation & Entrepreneurship (VLAIO) and the Charcot-Marie-Tooth Research Foundation (CMTRF), a US-based patient advocacy group.
Stay tuned for the upcoming positions!
We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.
